Pediatric Respiratory Tract Infection
Combination therapy shows safety, tolerability for young children with cystic fibrosis
Lumacaftor/ivacaftor appeared safe and well tolerated for up to 24 weeks in children aged 1 year to younger than 2 years homozygous for F508del-CFTR, according to a study in American Journal of Respiratory and Critical Care Medicine.
Rise in RSV cases anticipated as COVID-19 measures relax
As COVID-19 preventive measures begin to relax, authors of a commentary in the Canadian Medical Association Journal anticipate a resurgence in childhood respiratory syncytial virus in Canada.
Safety, tolerability of combination therapy sustained in children with cystic fibrosis
Combination therapy with lumacaftor/ivacaftor was safe and well tolerated for up to 120 weeks in children aged 6 to 11 years with the F508del-CFTR mutation for cystic fibrosis, according to results of an open-label, extension study.
Cannulas with long, narrow tubing noninferior to short binasal prongs in preterm infants
Use of cannulas with long and narrow tubing was noninferior to short binasal prongs and masks for providing nasal intermittent positive pressure ventilation in preterm infants, according to a study published in JAMA Pediatrics.